logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

BridgeBio Pharma Has Promising News

BridgeBio Pharma Granted Fast Track Designation for Encaleret BridgeBio Pharma ( BBIO ) announced the U.S. FDA granted Fast Track designation for Encaleret – a treatment of autosomal dominant hypocalcemia ( ADH1 ), on World Hypoparathyroidism Awareness Day, an annual...

Read More

June 2, 2021

0

Why Syndax and Incyte Traded UP in Today’s Early Morning  

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals ( SNDX ) and Incyte ( INCY ) announced positive data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease ( GVHD ) following...

Read More

July 24, 2023

0

Intellia Therapeutics Gene Editing Product NTLA-2001 - A Dream on its Way to Becoming Reality

Focus on Intellia Therapeutics Upcoming Presentation for NTLA-2001 Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June 26 Intellia Therapeutics NTLA-2001 for People Living with...

Read More

June 4, 2021

0

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Merck and Moderna Inc Announcement Merck ( MRK ) and Moderna Inc ( MRNA )  announced the initiation of the pivotal Phase 3 randomized V940-001clinical trial evaluating V940 ( mRNA- 4157 ), an investigational individualized neoantigen therapy ( INT ),...

Read More

July 26, 2023

0

The FDA Lifts the Clinical Holds on bluebird bio Gene Therapies in Clinical Trials

Clinical Holds on bluebird bio Gene Therapies were Lifted by the FDA The U.S. FDA has lifted the clinical holds on the bluebird bio ( BLUE ) Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell...

Read More

June 7, 2021

0

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

Merck KEYTRUDA Announcement Merck ( MRK ) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination with chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival ( PFS ) in patients with stage III-IV or recurrent...

Read More

February 3, 2023

0

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen ( IMGN ) , a leader in the expanding field of antibody-drug conjugates ( ADCs ) for the treatment of cancer, today reviewed recent progress in the business and...

Read More

July 31, 2023

0

The U.S. FDA Approves Vertex Pharmaceuticals TRIKAFTA for Children with Cystic Fibrosis Aged 6 to 11 with Certain Mutations

Vertex Pharmaceuticals Receives FDA Approval for TRIKAFTA ® Vertex Pharmaceuticals ( VRTX ) announced the U.S. FDA approved the expanded use of TRIKAFTA® to include children with cystic fibrosis ( CF ) ages 6 through 11 years who have at least...

Read More

June 9, 2021

0

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM  TODAY CymaBay Therapeutics, Inc. ( CBAY ) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic...

Read More

August 10, 2023

0

Veracyte Inc: Exciting News About nmCRPC Published Online

Veracyte Inc Decipher® Prostate Test Veracyte Inc ( VCYT ) : New data that demonstrated the prognostic utility of its Decipher® Prostate genomic classifier in men with non-metastatic castration-resistant prostate cancer ( nmCRPC ) has been published online in JAMA...

Read More

June 14, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 139
  • 140
  • 141
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy